Neurocrine Bio. (NBIX) Pipeline Remains Under Appreciated - RBC

RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $121.00 price target on Neurocrine Bio. (NASDAQ: NBIX) on the belief that pipeline programs, beyond Ingrezza, are underappreciated by the Street.

The analyst stated "our prior KOL feedback and analysis indicates that although NBIX’s congenital adrenal hyperplasia (CAH) program (NBI-74788) is still relatively early, the mechanistic rationale and results to date support a reasonable PoS for ’788 in reaching what we view as a relatively large market (est. ~$400M) for an orphan disease. We believe a number of important near-term clinical, regulatory, and competitive updates could help further de-risk the program and generate enthusiasm on potential diversification beyond Ingrezza, which we believe would catalyze share appreciation".

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $90.33 yesterday.

You May Also Be Interested In

• Neurocrine Bio. (NBIX) PT Lowered to $182 at Morgan Stanley
• SoundThinking (SSTI) PT Lowered to $8 at Cantor Fitzgerald
• Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald